Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EbolaCov
PACTR202407764378004Phase 4Not yet recruiting
- Sponsor
- University of Birmingham
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Ebola virus disease (EVD) comparing Concurrent Ervebo + Comirnaty with Ervebo + placebo (2 arms). Primary endpoints: Primary safety objective and Primary immunogenicity objective. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
Ebola Zaire vaccine (live, attenuated)tozinameran
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202407764378004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407764378004.